Andreas Tue Ingemann Jensen

Andreas Tue Ingemann Jensen is a Senior Researcher and Group Leader at DTU Health Technology, Technical University of Denmark. His research focuses on developing advanced radiopharmaceuticals and nanoparticle systems for targeted cancer therapy. He leads projects on brachytherapy seeds, radionuclide delivery, and blood-brain barrier penetration techniques at the Hevesy Laboratory.

His work integrates pharmaceutical science with nuclear medicine to create novel treatment approaches for prostate cancer, glioblastoma, and other malignancies. Current investigations include convection-enhanced drug delivery optimization and targeted alpha-therapy using astatine-211 compounds.

Jensen collaborates extensively on international projects and mentors PhD candidates in nanocarrier design and radiation oncology applications.